ResultsĬhildren ( N = 47) were randomised (intervention, 23 control, 24) in the fall. The main outcome was the change in serum 25OHD from baseline (Δ25OHD) over time and at 3.5 and 7 months other outcomes included the proportion of children with 25OHD ≥ 75 nmol/L, safety, and adverse event rates. Serum 25-hydroxyvitamin D (25OHD) was measured by tandem mass spectrometry at baseline, 10 days, 3.5 months, 3.5 months + 10 days, and 7 months.

Participants were allocated to receive two oral doses of 100,000 IU vitamin D 3 (intervention) or identical placebo (control) 3.5 months apart, once in the fall and once in the winter. We conducted a 7-month, triple-blind, randomised, placebo-controlled, pilot trial of children aged 1–5 years with viral-induced asthma. The objective was to ascertain the efficacy of high-dose vitamin D 3 in increasing serum vitamin D in preschoolers with asthma and provide preliminary data on safety and efficacy outcomes. New evidence supports the use of supplemental vitamin D in the prevention of exacerbation of asthma however, the optimal posology to sufficiently raise serum levels while maximising adherence is unclear.

Download 400 iu to ml